Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GABRD | O14764 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12969 | 1.00 | HPGD (1.00) | HPGDFAAHEPHX2NPC1RAB9A | |
| SCHEMBL1753626 | 0.98 | HPGD (0.97) | HPGDFAAHEPHX2NPC1RAB9A | |
| SCHEMBL2667152 | 0.95 | HPGD (0.90) | HPGDFAAHEPHX2GABRDGABRA1 | |
| SCHEMBL7130857 | 0.91 | HPGD (0.83) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL14238822 | 0.91 | HPGD (0.83) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL7127339 | 0.87 | HPGD (0.77) | HPGDNPC1RAB9ALMNAPOLB | |
| SCHEMBL10862335 | 0.87 | HPGD (0.76) | HPGDFAAHEPHX2RAB9AHTT | |
| SCHEMBL10720984 | 0.85 | HPGD (0.76) | HPGDLMNAPOLBHTTALDH1A1 | |
| SCHEMBL8360507 | 0.85 | HPGD (0.73) | HPGDGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL12563716 | 0.85 | HPGD (0.73) | HPGDNPC1GABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3277380-B1 | DNA ALKYLATING AGENTS | OBI PHARMA INC (TW) | 2020-09-16 | — | — | EP | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3290404-A1 | 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF [(5-(HALOPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ALKANOIC ACID DERIVATIVES | Akebia Therapeutics Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9908852-B2 | Bipyridyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-06 | — | — | US | disclosed |
| US-20170362178-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9776969-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3000808-B1 | 5-((HALOPHENYL)-3-HYDROXY-PYRIDIN-2-YL)-CARBOXYLIC ACID DERIVATIVES AS INTERMEDIATES FOR THE PREPARATION OF CARBONYLAMINO ALKANOIC ACIDS, ESTERS AND AMIDES THEREOF | AKEBIA THERAPEUTICS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170001960-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20150361043-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9145366-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362178-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | HPGD 39/4885FAAH 60/4885EPHX2 239/4885 |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | HPGD 518/4885FAAH 1189/4885EPHX2 1489/4885 |
| US-20170001960-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | HPGD 959/4885FAAH 4006/4885EPHX2 2650/4885 |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | HPGD 959/4885FAAH 4006/4885EPHX2 2650/4885 |
| US-20150361043-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | HPGD 39/4885FAAH 60/4885EPHX2 238/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | HPGD 449/4885FAAH 1182/4885EPHX2 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.